Callahan Advisors LLC Cuts Stake in Celgene Co. (CELG)

Callahan Advisors LLC decreased its holdings in Celgene Co. (NASDAQ:CELG) by 2.3% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,833 shares of the biopharmaceutical company’s stock after selling 687 shares during the period. Callahan Advisors LLC’s holdings in Celgene were worth $2,720,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Regent Investment Management LLC boosted its position in Celgene by 2.5% during the 1st quarter. Regent Investment Management LLC now owns 43,123 shares of the biopharmaceutical company’s stock valued at $4,068,000 after buying an additional 1,045 shares during the period. Financial Gravity Wealth Inc. purchased a new stake in Celgene during the 1st quarter valued at $349,000. Asset Dedication LLC boosted its position in Celgene by 35.5% during the 1st quarter. Asset Dedication LLC now owns 477 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 125 shares during the period. Bowling Portfolio Management LLC boosted its position in Celgene by 48.7% during the 1st quarter. Bowling Portfolio Management LLC now owns 73,782 shares of the biopharmaceutical company’s stock valued at $6,961,000 after buying an additional 24,155 shares during the period. Finally, Selway Asset Management boosted its position in Celgene by 3.6% during the 1st quarter. Selway Asset Management now owns 28,553 shares of the biopharmaceutical company’s stock valued at $2,694,000 after buying an additional 1,000 shares during the period. 74.81% of the stock is owned by institutional investors.

Shares of NASDAQ:CELG traded down $0.48 on Monday, hitting $93.28. The company had a trading volume of 265,339 shares, compared to its average volume of 11,263,870. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $95.44. The company has a current ratio of 2.23, a quick ratio of 2.12 and a debt-to-equity ratio of 3.21. The stock has a market cap of $65.67 billion, a price-to-earnings ratio of 12.26, a P/E/G ratio of 0.43 and a beta of 1.71.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.32 by $0.07. Celgene had a net margin of 26.48% and a return on equity of 114.66%. The firm had revenue of $4.04 billion during the quarter, compared to analysts’ expectations of $3.98 billion. During the same period last year, the company posted $2.00 EPS. Equities analysts forecast that Celgene Co. will post 10.01 EPS for the current fiscal year.

Several equities research analysts have weighed in on CELG shares. Cantor Fitzgerald cut shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 price target for the company. in a research report on Friday, April 5th. Cowen started coverage on shares of Celgene in a research report on Tuesday, February 26th. They set a “market perform” rating and a $102.00 price target for the company. BidaskClub raised shares of Celgene from a “strong sell” rating to a “sell” rating in a research report on Friday, January 4th. ValuEngine raised shares of Celgene from a “sell” rating to a “hold” rating in a research report on Saturday, March 30th. Finally, Zacks Investment Research cut shares of Celgene from a “buy” rating to a “hold” rating in a research report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $99.41.

In related news, Director Ernest Mario bought 2,000 shares of the company’s stock in a transaction dated Tuesday, February 12th. The stock was purchased at an average cost of $89.99 per share, with a total value of $179,980.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James J. Loughlin sold 23,466 shares of the firm’s stock in a transaction dated Thursday, February 7th. The stock was sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the completion of the sale, the director now directly owns 62,102 shares of the company’s stock, valued at $5,420,883.58. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/04/22/callahan-advisors-llc-cuts-stake-in-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: What are convertible shares? 

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.